Lineage Cell Therapeutics annual operating margin
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Lineage Cell Therapeutics Operating Margin Growth & History (LCTX)
Lineage Cell Therapeutics's operating margin was −251.57% for fiscal 2025.
View full Lineage Cell Therapeutics company overviewLineage Cell Therapeutics annual operating margin history
| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −251.57% | −25.47 pp |
| 2024 | 2024-12-31 | −226.11% | +50.39 pp |
| 2023 | 2023-12-31 | −276.50% | −123.33 pp |
| 2022 | 2022-12-31 | −153.17% | +980.47 pp |
| 2021 | 2021-12-31 | −1,133.63% | +314.72 pp |
| 2020 | 2020-12-31 | −1,448.36% | −342.35 pp |
| 2019 | 2019-12-31 | −1,106.00% | −268.09 pp |
| 2018 | 2018-12-31 | −837.91% | +287.07 pp |
| 2017 | 2017-12-31 | −1,124.99% | −129.43 pp |
| 2016 | 2016-12-31 | −995.56% | −60.24 pp |
| 2015 | 2015-12-31 | −935.32% | +31.16 pp |
| 2014 | 2014-12-31 | −966.48% | +296.18 pp |
| 2013 | 2013-12-31 | −1,262.65% | −624.12 pp |
| 2012 | 2012-12-31 | −638.53% | −217.11 pp |
| 2011 | 2011-12-31 | −421.42% | −155.72 pp |
| 2010 | 2010-12-31 | −265.70% | −82.84 pp |
| 2009 | 2009-12-31 | −182.86% | — |
Lineage Cell Therapeutics quarterly operating margin
Q2.10
Q3.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −834.71% | −119.33 pp |
| Q1 2026 | 2026-03-31 | −440.17% | −7.08 pp |
| Q4 2025 | 2025-12-31 | −99.09% | +79.08 pp |
| Q3 2025 | 2025-09-30 | −102.85% | −1.24 pp |
| Q2 2025 | 2025-06-30 | −715.37% | −298.68 pp |
| Q1 2025 | 2025-03-31 | −433.09% | +28.20 pp |
| Q4 2024 | 2024-12-31 | −178.17% | +126.52 pp |
| Q3 2024 | 2024-09-30 | −101.61% | +436.51 pp |
| Q2 2024 | 2024-06-30 | −416.69% | −260.91 pp |
| Q1 2024 | 2024-03-31 | −461.29% | −182.91 pp |
| Q4 2023 | 2023-12-31 | −304.69% | +41.99 pp |
| Q3 2023 | 2023-09-30 | −538.12% | −362.97 pp |
| Q2 2023 | 2023-06-30 | −155.78% | −53.71 pp |
| Q1 2023 | 2023-03-31 | −278.37% | −146.90 pp |
| Q4 2022 | 2022-12-31 | −346.68% | +2070.95 pp |
| Q3 2022 | 2022-09-30 | −175.15% | +2160.34 pp |
| Q2 2022 | 2022-06-30 | −102.07% | +3221.87 pp |
| Q1 2022 | 2022-03-31 | −131.47% | +1671.60 pp |
| Q4 2021 | 2021-12-31 | −2,417.64% | −760.74 pp |
| Q3 2021 | 2021-09-30 | −2,335.49% | −1157.74 pp |
| Q2 2021 | 2021-06-30 | −3,323.94% | −1665.39 pp |
| Q1 2021 | 2021-03-31 | −1,803.07% | −355.99 pp |
| Q4 2020 | 2020-12-31 | −1,656.90% | −1103.15 pp |
| Q3 2020 | 2020-09-30 | −1,177.76% | +307.60 pp |
| Q2 2020 | 2020-06-30 | −1,658.55% | −269.46 pp |
| Q1 2020 | 2020-03-31 | −1,447.08% | −71.97 pp |
| Q4 2019 | 2019-12-31 | −553.75% | +779.63 pp |
| Q3 2019 | 2019-09-30 | −1,485.36% | −430.68 pp |
| Q2 2019 | 2019-06-30 | −1,389.09% | −1030.08 pp |
| Q1 2019 | 2019-03-31 | −1,375.11% | +363.41 pp |
| Q4 2018 | 2018-12-31 | −1,333.38% | −321.42 pp |
| Q3 2018 | 2018-09-30 | −1,054.68% | −473.21 pp |
| Q2 2018 | 2018-06-30 | −359.01% | +1918.65 pp |
| Q1 2018 | 2018-03-31 | −1,738.52% | +1643.47 pp |
| Q4 2017 | 2017-12-31 | −1,011.96% | +8.26 pp |
| Q3 2017 | 2017-09-30 | −581.48% | +81.60 pp |
| Q2 2017 | 2017-06-30 | −2,277.66% | −1047.69 pp |
| Q1 2017 | 2017-03-31 | −3,381.98% | −2096.38 pp |
| Q4 2016 | 2016-12-31 | −1,020.22% | +641.88 pp |
| Q3 2016 | 2016-09-30 | −663.08% | +249.62 pp |
| Q2 2016 | 2016-06-30 | −1,229.97% | −458.33 pp |
| Q1 2016 | 2016-03-31 | −1,285.61% | +64.59 pp |
| Q4 2015 | 2015-12-31 | −1,662.10% | −796.93 pp |
| Q3 2015 | 2015-09-30 | −912.70% | +351.67 pp |
| Q2 2015 | 2015-06-30 | −771.64% | +756.08 pp |
| Q1 2015 | 2015-03-31 | −1,350.20% | −158.97 pp |
| Q4 2014 | 2014-12-31 | −865.17% | +888.87 pp |
| Q3 2014 | 2014-09-30 | −1,264.38% | +746.32 pp |
| Q2 2014 | 2014-06-30 | −1,527.72% | −743.91 pp |
| Q1 2014 | 2014-03-31 | −1,191.23% | +749.80 pp |
| Q4 2013 | 2013-12-31 | −1,754.03% | −1091.53 pp |
| Q3 2013 | 2013-09-30 | −2,010.70% | −1418.14 pp |
| Q2 2013 | 2013-06-30 | −783.81% | −195.67 pp |
| Q1 2013 | 2013-03-31 | −1,941.03% | −1004.95 pp |
| Q4 2012 | 2012-12-31 | −662.50% | −328.63 pp |
| Q3 2012 | 2012-09-30 | −592.55% | −228.19 pp |
| Q2 2012 | 2012-06-30 | −588.13% | +50.15 pp |
| Q1 2012 | 2012-03-31 | −936.08% | −447.63 pp |
| Q4 2011 | 2011-12-31 | −333.87% | — |
| Q3 2011 | 2011-09-30 | −364.37% | −62.91 pp |
| Q2 2011 | 2011-06-30 | −638.29% | −297.92 pp |
| Q1 2011 | 2011-03-31 | −488.45% | — |
| Q3 2010 | 2010-09-30 | −301.45% | — |
| Q2 2010 | 2010-06-30 | −340.36% | — |
Lineage Cell Therapeutics operating margin trends
Over the last five fiscal years, Lineage Cell Therapeutics's operating margin increased from −1,448.36% to −251.57%, a change of +1196.78 percentage points. The latest reported quarter, Q2 2026, shows −834.71%.
About the metric
What operating margin means
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
Calculation and source
How operating margin is calculated
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Lineage Cell Therapeutics source filings ↗